<ul data-eligibleForWebStory="false"><li>India is conducting phase-3 clinical trials for its first dengue vaccine with 8,000 participants receiving either the vaccine or a placebo across various centers.</li><li>The trial is sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec, with the results of the phase-1/2 trial showing no safety concerns for the one-shot vaccine.</li><li>The phase-3 trial, aiming to evaluate the vaccine's efficacy and safety, began in August last year and involves a multi-centre, double-blind, randomised, placebo-controlled approach.</li><li>Dengue is a significant public health issue in India, with the global incidence of the disease on the rise. Approximately 75-80% of dengue infections in India are asymptomatic, and the disease poses a higher risk for children and can lead to severe conditions in adults.</li></ul>

India’s first dengue vaccine: ICMR says phase-3 clinical trial enrolment to be completed by October

Discover more